The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Merck Discloses New Islatravir Data Supporting Safety Profile For PrEP Regime For HIV Infection
Merck & Co Inc (NYSE:MRK) has announced new data from Phase 2a trial evaluating islatravir for pre-exposure prophylaxis (PrEP) of HIV-1…
Merck Reports Data From Ongoing Phase 2a Trial Of Oral Islatravir For HIV-1 Prevention: Says Was Generally Well Tolerated, Most Adverse Events Were Mild, No Serious Drug-Related Adverse Events
Results from this study support the safety profile of oral islatravir PrEP regimen through 24 weeks versus placebo
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada,
New Ultra Shear Technology for Nanoemulsions Will Transform Multiple Large Markets; Latest Breakthrough From Pressure BioSciences
Photo by ThisIsEngineering from Pexels The leading developer of high-pressure-based platform technologies for life sciences applications worldwide, Pressure BioSciences (OTCQB:PBIO) (“PBI”)…
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE For The Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes; Under The Terms Of The Licensing Agreement With Merck, Ligand Earned A $2M Milestone Payment
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCETM, also known as V114, for the prevention of
Merck’s Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival
For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving…
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.
Unusual Options Activity Insight: Merck & Co
Merck & Co (NYSE:MRK) shares experienced unusual options activity on Friday. The stock price moved up to $78.07 following the option alert.
Merck Touts Encouraging Event-Free Survival For Keytruda Regime Over Placebo-Chemo Regime In Breast Cancer
Merck & Co Inc (NYSE:MRK) has announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522 trial…